Abstract
SARS-CoV-2 3C-like protease is the main protease of SARS-CoV-2 and has been considered as one of the key targets for drug discovery against COVID-19. We identified several N-substituted isatin compounds as potent SARS-CoV-2 3C-like protease inhibitors. The three most potent compounds inhibit SARS-CoV-2 3C-like protease with IC50’s of 45 nM, 47 nM and 53 nM, respectively. Our study indicates that N-substituted isatin compounds have the potential to be developed as broad-spectrum anti-coronavirus drugs.
Keywords: COVID-19, SARS-CoV-2 3C-like protease, N-substituted isatin compounds, In vitro assay, Structure-activity relationship
Graphical abstract
Highlights
-
•
SARS-CoV-2 3C-like protease is a key target for drug discovery against COVID-19.
-
•
N-substituted isatin compounds are potent SARS-CoV-2 3C-like protease inhibitors.
-
•
Three compounds showed 10 nM level inhibitory potency.
-
•
The most potent compound 26 demonstrates an IC50 of 45 nM.
1. Introduction
The coronavirus infectious disease 2019 (COVID-19) is a newly emerged infectious disease caused by a novel coronavirus, SARS-CoV-2 [1,2]. COVID-19 has been recognized as a global threat as it rapidly spreads and breaks out in many countries, causing significant health and economic impact. The SARS-CoV-2 is a positive-strand RNA virus that uses a complex set of enzymes to replicate its RNA genome [3,4]. Among these, the 3C-like protease (3CLpro), also known as the main protease (Mpro), is essential for processing the viral polyproteins that are translated from the viral RNA [5]. The active site of 3CLpro contains Cys145 and His41 to constitute a catalytic dyad, in which cysteine functions as the common nucleophile in the proteolytic process [6,7]. The catalytic domain of 3CLpro in CoVs is highly conserved [8]. Hence, 3CLpro has been considered as an attractive drug target for broad-spectrum anti-coronavirus therapy [4].
A variety of 3CLpro inhibitors have been reported in the literature over the past decade [4,[9], [10], [11], [12]]. To date, several potential SARS-CoV-2 3CLpro inhibitors have been reported from compound library screening [8], rational design [8,13,14] and testing of ingredients from traditional Chinese medicine [15,16]. The chemical structures of the experimentally identified SARS-CoV-2 3CLpro inhibitors are diverse, including α-ketoamide analogues [13], peptidomimetics compounds [8,14], baicalein and its derivatives [15,16] and several repurposed approved drugs and drug candidates [8]. However, only a few candidates have high inhibition activity against SARS-CoV-2 3CLpro and no effective therapy has been developed so far.
Previously, we reported a series of N-substituted 5-carboxamide-isatin compounds as inhibitors of SARS CoV 3CLpro [12]. The best compound showed a sub-micromolar IC50 against SARS-CoV 3CLpro [12]. Apparently, the isatin scaffold with derivatization may also provide a good starting point for SARS CoV-2 3CLpro inhibitor development, because the two proteases share high sequence identity and the same active site. In order to verify whether isatin compounds can inhibit SARS-CoV-2 3CLpro, we selected a series of isatin compounds from an in-house synthetic compound library, synthesized a few new compounds, tested their inhibitory effects against SARS-CoV-2 3CLpro, and analyzed their structure-activity relationship (SAR).
2. Results and discussion
2.1. Chemistry
The synthetic route used to prepare the test compounds 1–28 is shown in Scheme 1 . Compound 26 was resynthesized by a simple and effective synthetic route within three steps. First, 2-((4-carbamoylphenyl)amino)-2-oxoacetimidic acid (I-26) was obtained by reaction of 4-aminobenzamide, hydroxylamine hydrochloride, and chloral hydrate. Then, I-26 was converted into 2,3-dioxoindoline-5-carboxamide (II-26) by treatment with concentrated sulfuric acid at 90 °C. Last, 26 was obtained by reaction of 2,3-dioxoindoline-5-carboxamide (II-26) with 2-(bromomethyl)naphthalene.
Scheme 1.
aReagents and conditions: (a) Cl3CCH(OH)2, NH2OH•HCl, Na2SO4, H2O; (b) H2SO4; (c) K2CO3, R1X, acetonitrile.
The synthetic route used to prepare compound 29 is shown in Scheme 2 , which is different from other compounds. We started from 2-(4-aminophenyl)acetic acid using the general Sandmeyer synthetic route [12,17]. After got 2-(2,3-dioxoindolin-5-yl)acetic acid (II-29), additional carboxyl protection to change to methyl 2-(2,3-dioxoindolin-5-yl)acetate (III-29) with methyl group, followed by the introduction of naphthyl group at N1 position was subjected to afford methyl 2-(1-(naphthalen-2-ylmethyl)-2,3-dioxoindolin-5-yl)acetate (IV-29) and de-protection step to afford 2-(1-(naphthalen-2-ylmethyl)-2,3-dioxoindolin-5-yl)acetic acid (V-29). Then through activating the carboxyl group using phosphorus oxychloride, 29 was obtained by reaction of the activated V-29 and ammonium hydroxide. Compounds 1–25 were collected from our synthesized in-house library [12]. Compounds 27, 28 and 29 are new compounds that have not been reported before. The structures of the newly synthesized compounds 26, 27, 28 and 29 and the potent compound 23 were confirmed by 1H NMR, 13C NMR and HRMS.
Scheme 2.
aReagents and conditions: (a) Cl3CCH(OH)2, NH2OH•HCl, Na2SO4, H2O; (b) H2SO4; (c) EDC, dimethylaminopyridine, methanol; (d) K2CO3, 2-(Bromomethyl)naphthalene, acetonitrile; (e) NaOH, methanol; (f) i) POCl3; ii) ammonium hydroxide (30%), Et3N.
2.2. Biological evaluation
The inhibition activity was measured following the previously published procedure using a synthetic peptide-pNA as substrate (Table 1 ) [12,18]. We used Tideglusib as a positive control for the enzyme assay. Our measured IC50 value (1.91 μM) is in consistent with the reported one (1.55 μM,Fig. S1). 8 Among all the 29 compounds that we tested, 12 showed inhibition activity over 50% at 50 μM. Hydrophobic groups at the R1 position are required to insure the inhibitory effect. The carboxamide group at R2 position (23–28) is essential for the high inhibition activity. Compounds 26 and 23 inhibit SARS-CoV-2 3CLpro with IC50 values of 45 nM (Fig. 1 ) and 53 nM (Fig. S1), respectively. Further modifications at the 6-position of the naphthalene ring (27 and 28) were carried out to study the structure-activity relationship (SAR) of these compounds. Small substituents like 6-bromo in the naphthalene ring can be tolerated with a similar inhibition activity (IC50 of 47 nM, Fig. S1) of the parent compound 26. However, due to space limitation in the enzyme active site, large substituents like 6-phenyl group significantly reduced inhibitory effect (IC50 = 24.9 μM, Fig. S1). Substitution to other groups at R2 position like halogen (9), carboxylic acid N-hydroxysuccinimide ester (17) and ethanamide group (29) inactivate or decrease the activity of the compounds. The SARs of these compounds against SARS-CoV-2 3CLpro is similar to that found for SARS-CoV 3CLpro [12], further indicating that the substrate binding pocket in 3CLpro of CoVs is highly conserved and other classes of reported SARS-CoV or other CoVs 3CLpro inhibitors may also be effective against SARS-CoV-2 3CLpro.
Table 1.
Inhibition activities of isatin derivatives against SARS-CoV-2 3CLpro.
| Compds | R1 | R2 | IC50 or percentage (%) of inhibition at 50 μMb |
|---|---|---|---|
|
Tideglusiba |
1.91 ± 0.16 |
||
| 1 |  |
H | -c |
| 2 | -CH2OH | H | – |
| 3 |  |
F | – |
| 4 |  |
F | – |
| 5 |  |
Cl | – |
| 6 |  |
NO2 | – |
| 7 | CH3 | I | 25% at 50 μM |
| 8 | CH3CH2CH2 | I | 51% at 50 μM |
| 9 | n-C4H9 | I | 41.8 ± 8.0 |
| 10 | CH3 | CO2CH3 | 53% at 50 μM |
| 11 | CH3CH2CH2 | CO2CH3 | 53% at 50 μM |
| 12 | n-C4H9 | CO2CH3 | 42% at 50 μM |
| 13 |  |
CO2CH3 | 32% at 50 μM |
| 14 | PhCH2 | CO2CH3 | 45% at 50 μM |
| 15 | CH3 |  |
45% at 50 μM |
| 16 | n-C4H9 |  |
47% at 50 μM |
| 17 | PhCH2 |  |
15.5 ± 1.2 |
| 18 | CH3 | CO2H | – |
| 19 | CH3CH2CH2 | CO2H | – |
| 20 | n-C4H9 | CO2H | – |
| 21 | PhCH2 | CO2H | – |
| 22 | β-C10H7CH2 | CO2H | 32% at 50 μM |
| 23 |  |
CONH2 | 0.053 ± 0.010 |
| 24 | CH3CH2CH2 | CONH2 | 10.2 ± 1.0 |
| 25 | n-C4H9 | CONH2 | 17.8 ± 0.7 |
| 26 | β-C10H7CH2 | CONH2 | 0.045 ± 0.007 |
| 27 | β-(6-Br)-C10H7CH2 | CONH2 | 0.047 ± 0.007 |
| 28 | β-(6-Ph)-C10H7CH2 | CONH2 | 24.9 ± 4.6 |
| 29 | β-C10H7CH2 | CH2CONH2 | 39.2 ± 10.5 |
Fig. 1.
Dose-response curve of 26 against SARS-CoV-2 3CLpro.
2.3. Molecular docking study
To examine the potential binding mode of these compounds, we built the complex model structure of 26 and SARS-CoV-2 3CLpro using an induce-fit docking procedure. As shown in Fig. 2 , 26 fits snugly into the substrate-binding pocket. The carboxamide at C-5 makes H-bonds with the side-chain carboxyl groups of Asn142 and Glu166, and the oxygens at C-2 and C-3 form H-bonds with the main-chain amino group of Cys145. The naphthyl ring fits into the hydrophobic groove formed by Met49 and Met165 and forms π-π stacking interaction with His41.
Fig. 2.
The complex structure of compound 26 and SARS-CoV-2 3CLpro from docking study. The protein was shown in ribbons, and the compound 26 (yellow) and interacting residues in stick. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Combing the information from structure-activity relationship and docking analysis, we conclude that: (1) The carboxamide group at C-5 is essential for inhibition activity. Even adding one carbon between the carboxamide group and the isatin ring (29) was not tolerated. Replacing the carboxamide with carboxylic acid or ester group would destroy the hydrogen bond with Asn142 and bring in charge repulsion, making them unsuitable for binding. (2) The N-1 position of the isatin ring favors hydrophobic aromatic substituents. Aromatic group like naphthalene (26) or benzothiophene (23) made the molecule more rigid, fit into the pocket well and lead to high inhibition activity. Large substituents in the naphthalene ring significantly reduced activity (28).
3. Conclusion
In conclusion, we have tested the inhibition activity of 29 N-substituted isatin derivatives against SARS-CoV-2 3CLpro. The most potent compound, 26, demonstrated an IC50 of 45 nM against SARS-CoV-2 3CLpro, which is among the most potent SARS-CoV-2 3CLpro inhibitors known so far. We found that isatin compounds with a carboxamide substitution at the C-5 position and aromatic substitution at N-1 position are strong inhibitors of SARS-CoV-2 3CLpro. As these compounds also inhibit SARS-CoV 3CLpro, other known SARS-CoV 3CLpro inhibitors can be further tested for their inhibition activity against SARS-CoV-2 3CLpro. The active compounds have relatively high cytotoxicity that hinder quantitative measurement of their anti-SARS-CoV-2 activity (as shown in Fig. S2). Further optimization to reduce the cytotoxicity and to increase the cellular activity is necessary to develop this series of compounds as broad-spectrum anti-coronavirus drugs.
4. Experimental section
4.1. Synthesis
Melting points were obtained using an X4 apparatus and are uncorrected. Yields refer to isolated products. 1H NMR (400 MHz or 600 MHz) and 13C NMR (126 MHz or 151 MHz) spectra were measured on a Brucker APX 400 and Bruker-500 spectrometer using TMS as internal standard. The chemical shift values (δ) are reported in ppm relative to tetramethylsilane internal standard. 1H NMR spectra are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constant (J values) in Hz and integration. All reactions were monitored by thin layer chromatography (TLC), carried out on silica gel 60 F-254 aluminum sheets using UV, light (254 and 366 nm). The reagents and solvents were available commercially and purified according to conventional methods.
4.1.1. General procedure of the synthesis of compounds 1–28
4.1.1.1. Synthesis of I
2-((4-carbamoylphenyl)amino)-2-oxoacetimidic acid (I - 26). Solution A: A 500 mL, three-necked, round-bottomed flask fitted with a condenser and a thermometer was charged with 12.4 g (0.178 mol) of hydroxylamine hydrochloride, 52 g (0.37 mol) of anhydrous sodium sulfate, 14 g (0.085 mol) of chloral hydrate and 230 mL of water. To aid dissolution, the mixture was heated to approximately 70 °C and stirred vigorously with the help of a mechanical stirrer. Solution B: 9.52 g (0.07 mol) of 4-aminobenzamide was added dropwise slowly into a 50-mL round-bottomed flask containing a vigorously stirred mixture of 15 mL of water and 7.5 mL of concentrated sulfuric acid. Solution B was added in one portion to solution A. The mixture was vigorously stirred and heated to reflux. After cooling to room temperature the precipitate was collected by filtration and washed with ice-cold water. 12.31 g (85%) of product was obtained. The crude product is sufficiently pure for the next step.
4.1.1.2. Synthesis of II
2,3-dioxoindoline-5-carboxamide (II - 26). A 50-mL, two-necked, round-bottomed flask fitted with a thermometer was charged with 10 mL of concentrated sulfuric acid. After heating and stirring to 70 °C, 10 g (0.048 mol) of I-26 was added slowly to keep the temperature at 70 °C. The resulting deep red solution was heated to 90 °C for 30 min and then was cooled to room temperature (20 °C) over an ice bath. The mixture was then added rapidly to a vigorously stirred mixture of 100 m L of ice water and 20 mL of ethyl acetate. The organic phase was separated and the aqueous phase was extracted twice with 250 mL of ethyl acetate. The combined red organic phases were dried with sodium sulfate. The solvent was removed under reduced pressure and the crude product was purified by column chromatography. 0.092 g (1%) of an orange powder was obtained.
4.1.1.3. Synthesis of 1–26
1-(naphthalen-2-ylmethyl)-2,3-dioxoindoline-5-carboxamide (26). A mixture of II-26 (0.092 g, 0.48 mmol), 2-(Bromomethyl)naphthalene (0.117 g, 0.53 mmol) and K2CO3 (0.166 g, 1.20 mmol) in 40 mL of acetonitrile was heating to reflux for 10 h. After the reaction is completed monitored by TLC. The solution was evaporated and purified by column chromatography. 0.079 g (50%) of an orange powder is obtained. m.p.: 290–292 °C. 1H NMR (400 MHz, DMSO‑d 6) δ 8.10 (d, J = 1.8 Hz, 1H), 8.07 (dd, J = 8.2, 1.8 Hz, 1H), 8.03 (s, 1H), 8.01 (s, 1H), 7.91 (dd, J = 9.0, 4.8 Hz, 2H), 7.88–7.81 (m, 1H), 7.61–7.54 (m, 1H), 7.54–7.46 (m, 2H), 7.42 (s, 1H), 7.06 (d, J = 8.3 Hz, 1H), 5.11 (s, 2H). 13C NMR (126 MHz, DMSO‑d 6) δ 183.08, 166.71, 152.83, 137.71, 133.35, 133.3, 132.82, 129.60, 128.79, 128.06, 126.82, 126.50, 126.18, 125.96, 123.73, 118.16, 111.17, 43.76. HRMS (ESI+) calcd for C20H15N2O3 [M + H]+: 331.1004, found: 331.1077.
4.1.1.4. 1-(benzo[b]thiophen-2-ylmethyl)-2,3-dioxoindoline-5-carboxamide (23)
An orange powder. m.p.: 210–212 °C. 1H NMR (600 MHz, DMSO‑d 6) δ 8.16 (dd, J = 8.3, 1.8 Hz, 1H), 8.11 (d, J = 1.7 Hz, 1H), 8.05 (s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.80–7.74 (m, 1H), 7.59 (s, 1H), 7.43 (s, 1H), 7.34 (m, 3H), 5.25 (s, 2H). 13C NMR (151 MHz, DMSO‑d 6) δ 182.74, 166.68, 158.83, 152.34, 139.66, 139.53, 139.03, 137.87, 129.83, 125.04, 125.00, 124.05, 123.99, 123.88, 122.98, 118.06, 111.19, 39.51. HRMS (ESI+) calcd for C18H13N2O3S [M + H]+: 337.0569, found: 337.0641.
4.1.1.5. 1-((6-Bromonaphthalen-2-yl)methyl)-2,3-dioxoindoline-5-carboxamide (27)
An orange powder. m.p.: 269–271 °C. Yield: 35%. 1H NMR (400 MHz, DMSO‑d 6) δ 8.19 (d, J = 1.9 Hz, 1H), 8.11 (d, J = 1.8 Hz, 1H), 8.07 (dd, J = 8.3, 1.9 Hz, 1H), 8.03 (s, 2H), 7.91 (d, J = 8.5 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.62 (dd, J = 8.9, 1.9 Hz, 2H), 7.40 (s, 1H), 7.05 (d, J = 8.3 Hz, 1H), 5.10 (s, 2H). 13C NMR (101 MHz, DMSO‑d 6) δ 183.02, 166.71, 159.37, 152.75, 137.70, 134.12, 133.99, 131.86, 130.32, 129.95, 129.79, 129.60, 128.03, 127.18, 126.13, 123.74, 119.62, 118.20, 111.11, 43.65. HRMS (ESI+) calcd for C20H14BrN2O3 [M + H]+: 409.0110, found: 409.0182.
4.1.1.6. 2,3-Dioxo-1-((6-phenylnaphthalen-2-yl)methyl)indoline-5-carboxamide (28)
An orange powder. m.p.: 263–265 °C. Yield: 12%. 1H NMR (400 MHz, DMSO‑d 6) δ 8.21 (d, J = 1.8 Hz, 1H), 8.11 (d, J = 1.9 Hz, 1H), 8.08 (dd, J = 8.2, 1.9 Hz, 1H), 8.05–7.92 (m, 4H), 7.83 (m, 3H), 7.60 (dd, J = 8.5, 1.8 Hz, 1H), 7.51 (t, J = 7.7 Hz, 2H), 7.44–7.35 (m, 2H), 7.07 (d, J = 8.3 Hz, 1H), 5.13 (s, 2H). 13C NMR (101 MHz, DMSO‑d 6) δ 166.72, 159.37, 152.83, 140.30, 138.03, 137.71, 133.49, 133.17, 132.58, 129.49, 129.24, 128.78, 128.06, 127.40, 126.43, 125.95, 125.54, 123.74, 118.18, 111.19, 43.78. 13C NMR (101 MHz, DMSO‑d 6) δ 183.09, 166.72, 159.37, 152.83, 140.30, 138.03, 137.71, 133.49, 133.17, 132.58, 129.59, 129.49, 129.24, 128.78, 128.06, 127.40, 126.43, 125.95, 125.54, 123.74, 118.18, 111.19, 43.78. HRMS (ESI+) calcd for C26H19N2O3 [M + H]+: 407.1317, found: 407.1390.
4.1.2. Synthesis of compound 29
4.1.2.1. Methyl 2-(2,3-dioxoindolin-5-yl)acetate (III-29)
To a stirred solution of methanol (50 ml) were added 2-(2,3-dioxoindolin-5-yl)acetic acid II-29 (2g, 9.7 mmol), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (2.22 g, 11.6 mmol) and 4-dimethylaminopyridine (0.061 g, 0.5 mmol) at 25 °C. After stirring for 3h, the reaction was quenched with 20 ml water. The mixture was extracted with EtOAc and the organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. 1.46 g (70%) of product is obtained. The crude product is sufficiently pure for the next step.
4.1.2.2. Methyl 2-(1-(naphthalen-2-ylmethyl)-2,3-dioxoindolin-5-yl)acetate (IV-29)
A mixture of III-29 (1 g, 4.6 mmol), 2-(Bromomethyl)naphthalene (1.17 g, 5.3 mmol) and K2CO3 (1.63 g, 11.8 mmol) in 100 mL of acetonitrile was heating to reflux for 10 h. After the reaction was completed monitored by TLC. The solution was evaporated and purified by column chromatography. 1.062 g (63%) of a red powder is obtained. 1H NMR (400 MHz, DMSO‑d 6) δ 7.99 (s, 1H), 7.95–7.80 (m, 3H), 7.58–7.47 (m, 4H), 7.44 (dd, J = 8.0, 1.7 Hz, 1H), 6.94 (d, J = 8.1 Hz, 1H), 5.07 (s, 2H), 3.68 (s, 2H), 3.58 (s, 3H).
4.1.2.3. 2-(1-(naphthalen-2-ylmethyl)-2,3-dioxoindolin-5-yl)acetic acid (V-29)
Methyl ester IV-29 (1g, 2.78 mmol) was dissolved in 100 ml methanol. NaOH (0.117 g, 2.92 mmol) was added to this solution. The mixture was stirred at 55–60 °C for 1 h. After cooling to the room temperature, 20 ml 3 N HCl was added. The precipitate was collected by filtration and washed with ice-cold water twice. 0.859 g (89%) of an orange power is obtained.
4.1.2.4. 2-(1-(naphthalen-2-ylmethyl)-2,3-dioxoindolin-5-yl)acetamide (29)
To a stirred solution of EtOAc (5 ml) and THF (5 ml) added compound V-29 (30 mg, 0.08 mmol), POCl3 (110 mg, 0.71 mmol) over an ice bath. The mixture was stirred for additional 30 min. Then the resulting solution was adder to another mixture containing 5 ml acetonitrile, 30% ammonium hydroxide (0.560 g, 10 mmol) and Et3N (1.01 g, 10 mmol). After the reaction completed, the mixture was extracted with EtOAc and the organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography to give the 29 (15 mg, 57%) as an orange powder. m.p.: 200–202 °C. 1H NMR (400 MHz, DMSO‑d 6) δ 7.98 (s, 1H), 7.96–7.81 (m, 3H), 7.60–7.44 (m, 5H), 7.40 (dd, J = 8.2, 1.9 Hz, 1H), 6.92 (d, J = 8.1 Hz, 2H), 5.07 (s, 2H), 3.34 (s, 2H). 13C NMR (126 MHz, DMSO‑d 6) δ 172.94, 149.48, 139.36, 133.50, 133.35, 132.82, 130.85, 128.82, 128.08, 128.04, 126.81, 126.48, 126.22, 125.93, 118.16, 111.32, 43.65, 39.78. HRMS (ESI+) calcd for C21H17N2O3 [M + H]+: 345.1161, found: 345.1234.
4.2. Molecular docking
The crystal structure of SARS-CoV-2 3CLpro (PDB ID 6LU7) was used for molecular docking [8]. The structures of the protein and 26 were prepared by Protein Preparation Wizard and LigPrep module, respectively. The binding pocket was defined as a 20∗20∗20 Å3 cubic box centered to the centroid of Cys145. Flexible docking was conducted using the Induced Fit Docking module in GLIDE. Standard protocol and XP precision were used. Ten conformations were generated and scored by glidescore. The best scored conformation was used for structural analysis. All the above mentioned modules were implemented in Schrödinger version 2015-4 (Schrödinger software suite, L. L. C. New York, NY (2015).)
4.3. Biology
4.3.1. Cloning, expression and purification of SARS-CoV-2 3CLpro
The full-length gene encoding SARS-CoV-2 3CLpro was synthesized for Escherichia coli (E. coli) expression (Hienzyme Biotech). The expression and purification of SARS-CoV-2 3CLpro were carried out using the reported protocol [15].
4.3.2. Enzyme assay
A colorimetric substrate Thr-Ser-Ala-Val-Leu-Gln-pNA (GL Biochemistry Ltd) and assay buffer (40 mM PBS, 100 mM NaCl, 1 mM EDTA, 0.1% Triton 100, pH 7.3) was used for the inhibition assay. To evaluate the effects of compounds on SARS-CoV-2 3CL protease activity, compounds were first pre-incubated with enzyme samples in the assay buffer for 30 min at room temperature. And then 10 μl of 2 mM substrate was added into the above system to the final concentration of 200 μM to initiate the reaction. Increase in absorbance at 390 nm was recorded for 20 min at an interval of 30s with a kinetics mode program using a plate reader (Synergy, Biotek). IC50 values were fitted with Hill1 function.
Declaration of competing interest
The authors declare that they have no conflicts of interest to this work.
Acknowledgements
This work was supported in part by the National Natural Science Foundation of China (21633001,21877003), and the Ministry of Science and Technology of China (2016YFA0502303).
Footnotes
Supplementary data associated with this article can be found in the online version, at https://doi.org/10.1016/j.ejmech.2020.112702. These data include MOL files and InChiKeys of the most important compounds described in this article.
Abbreviations
- COVID-19
CoV infectious disease
- 3CLpro
3C-like protease
- TLC
thin layer chromatography
Appendix. Supplementary data
MOL Files
The following ZIP file contains the MOL files of the most important compounds referred to in this article.
ZIP file containing the MOL files of the most important compounds in this article.
References
- 1.Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G.F., Tan W., China Novel Coronavirus I., Research T. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/nejmoa2001017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J., Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zumla A., Chan J.F., Azhar E.I., Hui D.S., Yuen K.Y. Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discov. 2016;15:327–347. doi: 10.1038/nrd.2015.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Pillaiyar T., Manickam M., Namasivayam V., Hayashi Y., Jung S.H. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J. Med. Chem. 2016;59:6595–6628. doi: 10.1021/acs.jmedchem.5b01461. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281:4085–4096. doi: 10.1111/febs.12936. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763–1767. doi: 10.1126/science.1085658. [DOI] [PubMed] [Google Scholar]
- 7.Du Q.S., Wang S.Q., Zhu Y., Wei D.Q., Guo H., Sirois S., Chou K.C. Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of the octapeptide. Peptides. 2004;25:1857–1864. doi: 10.1016/j.peptides.2004.06.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X., You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W., Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020;582:289–293. doi: 10.1038/s41586-020-2223-y. [DOI] [PubMed] [Google Scholar]
- 9.Konno H., Onuma T., Nitanai I., Wakabayashi M., Yano S., Teruya K., Akaji K. Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor. Bioorg. Med. Chem. Lett. 2017;27:2746–2751. doi: 10.1016/j.bmcl.2017.04.056. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Ohnishi K., Hattori Y., Kobayashi K., Akaji K. Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor. Bioorg. Med. Chem. 2019;27:425–435. doi: 10.1016/j.bmc.2018.12.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Yoshizawa S.I., Hattori Y., Kobayashi K., Akaji K. Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor. Bioorg. Med. Chem. 2020;28:115273. doi: 10.1016/j.bmc.2019.115273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Zhou L., Liu Y., Zhang W.L., Wei P., Huang C.K., Pei J.F., Yuan Y.X., Lai L.H. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors. J. Med. Chem. 2006;49:3440–3443. doi: 10.1021/jm0602357. [DOI] [PubMed] [Google Scholar]
- 13.Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science. 2020;368:409–412. doi: 10.1126/science.abb3405. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C., Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X., Xiao G., Jiang H., Rao Z., Zhang L.-K., Xu Y., Yang H., Liu H. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020:eabb4489. doi: 10.1126/science.abb4489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Liu H., Ye F., Sun Q., Liang H., Li C., Lu R., Huang B., Tan W., Lai L. 2020. Extract and Baicalein Inhibit Replication of SARS-CoV-2 and its 3C-like Protease. bioRxiv. 2020.2004.2010.035824. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Su H., Yao S., Zhao W., Li M., Liu J., Shang W., Xie H., Ke C., Gao M., Yu K., Liu H., Shen J., Tang W., Zhang L., Zuo J., Jiang H., Bai F., Wu Y., Ye Y., Xu Y. 2020. Discovery of Baicalin and Baicalein as Novel, Natural Product Inhibitors of SARS-CoV-2 3CL Protease. bioRxiv. 2020.2004.2013.038687. [DOI] [Google Scholar]
- 17.Sandmeyer T. Über isonitrosoacetanilide und deren Kondensation zu Isatinen. Helv. Chim. Acta. 1919;2:234–242. doi: 10.1002/hlca.19190020125. [DOI] [Google Scholar]
- 18.Huang C., Wei P., Fan K., Liu Y., Lai L. 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry. 2004;43:4568–4574. doi: 10.1021/bi036022q. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
ZIP file containing the MOL files of the most important compounds in this article.